HC Wainwright & Co. Maintains Buy on Zevra Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Zevra Therapeutics and raised the price target from $18 to $20, indicating confidence in the company's future performance.
September 20, 2024 | 5:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Zevra Therapeutics and increased the price target from $18 to $20, suggesting a positive outlook for the company's stock.
The increase in the price target from $18 to $20 by HC Wainwright & Co. reflects a positive sentiment and confidence in Zevra Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price as investors may view the raised target as a sign of potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100